Vyndamax
Generic name:tafamidis [ ta-FAM-id-is ]
Dosage form: oral capsule 61mg
Drug class:Transthyretin stabilizers
What is Vyndamax?
Vyndamax affects a protein called transthyretin (TTR, made primarily in the liver). Transthyretin-mediated amyloidosis (ATTR) is a condition in which abnormal deposits of TTR protein build-up in many parts of the body, interfering with normal function. A build-up of TTR in the heart can lead to heart failure.
People with hereditary ATTR amyloidosis have a DNA mutation that can be passed from one generation to the next. People with wild-type ATTR amyloidosis do not have abnormal DNA and cannot pass on the condition.
Vyndamax is used in adults with hereditary or wild type ATTR to treat cardiomyopathy (damage of the heart muscle) caused by a build-up of TTR.
Warnings
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Before taking this medicine
To make sure Vyndamax is safe for you, tell your doctor if you have:
Your name may be listed on a Transthyretin Amyloidosis Outcome Survey registry to track the effects of tafamidis on your condition.
Tafamidis may harm an unborn baby. Use effective birth control to prevent pregnancy, and tell your doctor if you become pregnant.
If you become pregnant, tell your doctor or contact the manufacturer of Vyndamax at 1-800-438-1985.
You should not breastfeed while using Vyndamax.
How should I take Vyndamax?
Take Vyndamax exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Take Vyndamax exactly as your doctor has recommended. Avoid medication errors by using only the form and strength your doctor prescribes.
Swallow the capsule whole and do not crush, chew, break, or open it.
You may take Vyndamax with or without food.
Store at room temperature away from moisture and heat. Keep each capsule in the blister pack until you are ready to take a dose.
Dosing information
Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis:
Tafamidis 61 mg: 1 capsule once a day (61 mg/day)
Comments: Tafamidis and tafamidis meglumine products are not substitutable on a per mg basis.
Use: For the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.